Comparative Pharmacology
Head-to-head clinical analysis: NAPHCON FORTE versus PREFRIN A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAPHCON FORTE versus PREFRIN A.
NAPHCON FORTE vs PREFRIN-A
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naphazoline acts as an agonist at alpha-adrenergic receptors in the vascular smooth muscle of the conjunctiva, causing vasoconstriction and reducing redness.
PREFRIN-A contains phenylephrine, an alpha-1 adrenergic receptor agonist, and acetaminophen, a centrally acting analgesic and antipyretic. Phenylephrine causes vasoconstriction in nasal mucosa, reducing congestion. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the brain, reducing prostaglandin synthesis.
1-2 drops of 0.1% solution in the affected eye(s) every 3-4 hours as needed.
1 drop in each affected eye every 3-4 hours as needed, not to exceed 4 times daily.
None Documented
None Documented
Terminal elimination half-life is 9-11 hours; clinically, steady state is reached after 2-3 days of regular dosing.
Terminal elimination half-life: 2-4 hours in adults; 6-12 hours in neonates and infants due to immature hepatic metabolism.
Renal excretion of unchanged drug (65%) and metabolites (35%); less than 1% fecal.
Renal: 70-80% as unchanged drug and metabolites; biliary/fecal: 20-30% as metabolites.
Category C
Category C
Ophthalmic Decongestant
Ophthalmic Decongestant/Antihistamine Combination